Department of Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA.
Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, WA 98195, USA.
Endocrinology. 2023 Mar 13;164(5). doi: 10.1210/endocr/bqad055.
The peptidase neprilysin modulates glucose homeostasis by cleaving and inactivating insulinotropic peptides, including some produced in the intestine such as glucagon-like peptide-1 (GLP-1). Under diabetic conditions, systemic or islet-selective inhibition of neprilysin enhances beta-cell function through GLP-1 receptor (GLP-1R) signaling. While neprilysin is expressed in intestine, its local contribution to modulation of beta-cell function remains unknown. We sought to determine whether acute selective pharmacological inhibition of intestinal neprilysin enhanced glucose-stimulated insulin secretion under physiological conditions, and whether this effect was mediated through GLP-1R. Lean chow-fed Glp1r+/+ and Glp1r-/- mice received a single oral low dose of the neprilysin inhibitor thiorphan or vehicle. To confirm selective intestinal neprilysin inhibition, neprilysin activity in plasma and intestine (ileum and colon) was assessed 40 minutes after thiorphan or vehicle administration. In a separate cohort of mice, an oral glucose tolerance test was performed 30 minutes after thiorphan or vehicle administration to assess glucose-stimulated insulin secretion. Systemic active GLP-1 levels were measured in plasma collected 10 minutes after glucose administration. In both Glp1r+/+ and Glp1r-/- mice, thiorphan inhibited neprilysin activity in ileum and colon without altering plasma neprilysin activity or active GLP-1 levels. Further, thiorphan significantly increased insulin secretion in Glp1r+/+ mice, whereas it did not change insulin secretion in Glp1r-/- mice. In conclusion, under physiological conditions, acute pharmacological inhibition of intestinal neprilysin increases glucose-stimulated insulin secretion in a GLP-1R-dependent manner. Since intestinal neprilysin modulates beta-cell function, strategies to inhibit its activity specifically in the intestine may improve beta-cell dysfunction in type 2 diabetes.
肽酶 Neprilysin 通过切割和失活胰岛素促分泌肽来调节葡萄糖稳态,包括一些在肠道中产生的肽,如胰高血糖素样肽-1 (GLP-1)。在糖尿病条件下,系统性或胰岛选择性抑制 Neprilysin 通过 GLP-1 受体 (GLP-1R) 信号增强β细胞功能。虽然 Neprilysin 在肠道中表达,但它对β细胞功能调节的局部贡献尚不清楚。我们试图确定急性选择性肠道 Neprilysin 药理学抑制是否在生理条件下增强葡萄糖刺激的胰岛素分泌,以及这种作用是否通过 GLP-1R 介导。瘦鼠喂养的 Glp1r+/+ 和 Glp1r-/- 小鼠接受单次口服低剂量 Neprilysin 抑制剂硫普罗宁或载体。为了确认肠道 Neprilysin 的选择性抑制,在给予硫普罗宁或载体 40 分钟后评估血浆和肠道(回肠和结肠)中的 Neprilysin 活性。在另一批小鼠中,在给予硫普罗宁或载体 30 分钟后进行口服葡萄糖耐量试验,以评估葡萄糖刺激的胰岛素分泌。在给予葡萄糖后 10 分钟收集的血浆中测量系统活性 GLP-1 水平。在 Glp1r+/+ 和 Glp1r-/- 小鼠中,硫普罗宁抑制回肠和结肠中的 Neprilysin 活性,而不改变血浆 Neprilysin 活性或活性 GLP-1 水平。此外,硫普罗宁显著增加 Glp1r+/+ 小鼠的胰岛素分泌,而在 Glp1r-/- 小鼠中则没有改变胰岛素分泌。总之,在生理条件下,急性肠道 Neprilysin 药理学抑制以 GLP-1R 依赖的方式增加葡萄糖刺激的胰岛素分泌。由于肠道 Neprilysin 调节β细胞功能,因此抑制其在肠道中的活性的策略可能会改善 2 型糖尿病中的β细胞功能障碍。